128 related articles for article (PubMed ID: 36764685)
1. Analysis of FDA's Vuse market authorisation: limitations and opportunities.
Meshnick AB; Faricy LE; Lushniak BD
Tob Control; 2024 Mar; 33(e1):e116-e121. PubMed ID: 36764685
[TBL] [Abstract][Full Text] [Related]
2. Vuse Solo e-cigarettes do not provide net benefits to public health: a scientific analysis of FDA's marketing authorisation.
Glantz S; Lempert LK
Tob Control; 2024 Mar; 33(e1):e108-e115. PubMed ID: 36764683
[TBL] [Abstract][Full Text] [Related]
3. Analysis of FDA's IQOS marketing authorisation and its policy impacts.
Lempert LK; Glantz S
Tob Control; 2020 Jun; ():. PubMed ID: 32601147
[TBL] [Abstract][Full Text] [Related]
4. Public perceptions of the FDA's marketing authorization of Vuse on Twitter/X.
Lee S; Xie Z; Xu E; Shao Y; Ossip DJ; Li D
Front Public Health; 2023; 11():1280658. PubMed ID: 38026290
[TBL] [Abstract][Full Text] [Related]
5. Part one: abuse liability of Vuse Solo (G2) electronic nicotine delivery system relative to combustible cigarettes and nicotine gum.
Campbell C; Jin T; Round EK; Schmidt E; Nelson P; Baxter S
Sci Rep; 2022 Dec; 12(1):22080. PubMed ID: 36543869
[TBL] [Abstract][Full Text] [Related]
6. Comparison of design characteristics and toxicant emissions from Vuse Solo and Alto electronic nicotine delivery systems.
Talih S; Karaoghlanian N; Salman R; Fallah S; Helal A; El-Hage R; Saliba N; Breland A; Eissenberg T; Shihadeh A
Tob Control; 2023 Apr; ():. PubMed ID: 37072168
[TBL] [Abstract][Full Text] [Related]
7. Analysis of e-cigarette warning letters issued by the Food and Drug Administration in 2020 and 2021.
Schillo BA; Bertrand A; Briggs J; Kierstead EC; Silver NA; Yoon SN; Diaz MC
Tob Control; 2024 Feb; 33(2):247-251. PubMed ID: 36229228
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum.
Stiles MF; Campbell LR; Jin T; Graff DW; Fant RV; Henningfield JE
Psychopharmacology (Berl); 2018 Jul; 235(7):2077-2086. PubMed ID: 29725702
[TBL] [Abstract][Full Text] [Related]
9. History and Current Trends in the Electronic Cigarette Retail Marketplace in the United States: 2010-2016.
Cantrell J; Huang J; Greenberg M; Willett J; Hair E; Vallone D
Nicotine Tob Res; 2020 Apr; 22(5):843-847. PubMed ID: 30312465
[TBL] [Abstract][Full Text] [Related]
10. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
Lempert LK; Bialous S; Glantz S
Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability.
Stiles MF; Campbell LR; Graff DW; Jones BA; Fant RV; Henningfield JE
Psychopharmacology (Berl); 2017 Sep; 234(17):2643-2655. PubMed ID: 28634710
[TBL] [Abstract][Full Text] [Related]
12. Electronic nicotine delivery systems (ENDS) flavours and devices used by adults before and after the 2020 US FDA ENDS enforcement priority: findings from the 2018 and 2020 US ITC Smoking and Vaping Surveys.
Gravely S; Meng G; Hammond D; Reid JL; Seo YS; Hyland A; Cummings KM; Rivard C; Fong GT; Kasza KA
Tob Control; 2022 Nov; 31(Suppl 3):s167-s175. PubMed ID: 36328466
[TBL] [Abstract][Full Text] [Related]
13. Evidentiary Support in Public Comments to the FDA's Center for Tobacco Products.
Hemmerich N; Klein EG; Berman M
J Health Polit Policy Law; 2017 Aug; 42(4):645-666. PubMed ID: 28483810
[TBL] [Abstract][Full Text] [Related]
14. Tobacco Product Use and Associated Factors Among Middle and High School Students - National Youth Tobacco Survey, United States, 2021.
Gentzke AS; Wang TW; Cornelius M; Park-Lee E; Ren C; Sawdey MD; Cullen KA; Loretan C; Jamal A; Homa DM
MMWR Surveill Summ; 2022 Mar; 71(5):1-29. PubMed ID: 35271557
[TBL] [Abstract][Full Text] [Related]
15. Electronic nicotine delivery systems: the need for continued regulatory innovation.
Miller BJ; Meshnick AB; Lushniak BD
Tob Control; 2023 May; 32(3):375-380. PubMed ID: 34389688
[TBL] [Abstract][Full Text] [Related]
16. At the speed of Juul: measuring the Twitter conversation related to ENDS and Juul across space and time (2017-2018).
Kim Y; Emery SL; Vera L; David B; Huang J
Tob Control; 2021 Mar; 30(2):137-146. PubMed ID: 32198278
[TBL] [Abstract][Full Text] [Related]
17. Part three: a randomized study to assess biomarker changes in cigarette smokers switched to Vuse Solo or Abstinence.
Kanobe MN; Jones BA; Nelson P; Brown BG; Chen P; Makena P; Schmidt E; Darnell J; Caraway JW; Prasad GL; Nordskog B; Round EK
Sci Rep; 2022 Nov; 12(1):20658. PubMed ID: 36450821
[TBL] [Abstract][Full Text] [Related]
18. Abuse liability of two electronic nicotine delivery systems compared with combustible cigarettes and nicotine gum from an open-label randomized crossover study.
Campbell C; Jin T; Round EK; Nelson PR; Baxter S
Sci Rep; 2023 Nov; 13(1):18951. PubMed ID: 37919490
[TBL] [Abstract][Full Text] [Related]
19. IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation.
Berg CJ; Romm KF; Bar-Zeev Y; Abroms LC; Klinkhammer K; Wysota CN; Khayat A; Broniatowski DA; Levine H
Tob Control; 2023 Jul; 32(4):418-427. PubMed ID: 34667105
[TBL] [Abstract][Full Text] [Related]
20. JUUL's 2019 Removal of Mint-Flavored Pods and Changes to the Retail Environment of Electronic Nicotine Delivery Systems in Florida and the United States.
Gaber J; Gammon DG; Lee YO; Nonnemaker J; Young B; Kim A; Porter L
Nicotine Tob Res; 2022 Oct; 24(11):1748-1755. PubMed ID: 35569072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
